Researchers at Karolinska Institutet have identified a subset of immune cells—regulatory T cells (Tregs)—that can impede the efficacy of immune checkpoint inhibitors (ICIs) like pembrolizumab and nivolumab in treating advanced melanoma and non-small cell lung cancer (NSCLC). Published this week in Nature Immunology, the study reveals how these cells suppress anti-tumor responses, potentially explaining why some patients experience limited benefits from ICIs despite initial promise. The findings were funded by the Swedish Cancer Society and the European Research Council.
Why it matters: Immune checkpoint inhibitors have revolutionized oncology, achieving 30–40% objective response rates in metastatic NSCLC and melanoma [1]. Yet, up to 60% of patients fail to respond or develop resistance within 12–24 months [2]. This study pinpoints a critical biological barrier—Tregs—that may be sabotaging treatment before it reaches its full potential. For the 1.8 million patients globally diagnosed with NSCLC annually [WHO, 2025], and the 325,000 melanoma cases [Global Cancer Observatory], these insights could redefine combination therapies.
In Plain English: The Clinical Takeaway
- Immune checkpoint drugs (like Keytruda or Opdivo) “unlock” T cells to attack tumors—but Tregs act like traffic cops, slowing down this process.
- This discovery suggests targeting Tregs alongside ICIs could boost responses in non-responders, potentially adding 1–2 years of progression-free survival.
- Patients who don’t improve after 3 months of ICIs may now have a biological explanation—and a path to personalized adjustments.
How Tregs Sabotage Cancer Immunotherapy: The Molecular Mechanism
The Karolinska team used single-cell RNA sequencing to analyze tumor microenvironments in 47 treatment-resistant NSCLC and melanoma patients. They found that Tregs—a specialized immune cell type—overproduced CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) and PD-1 (programmed death-1), two proteins ICIs normally block. However, these cells also secreted IL-10 and TGF-β, creating an immunosuppressive “shield” around tumors.
Key finding: In patients with high Treg infiltration, ICI efficacy dropped by 42% compared to those with low infiltration (p = 0.002, adjusted for tumor mutational burden) [3]. “We’re not just talking about reduced responses—we’re seeing a near-complete shutdown of the anti-tumor immune cascade,” said Dr. Anna Lindström, lead author and associate professor of immunology at Karolinska.
“This is the first time we’ve mapped how Tregs actively rewrite the tumor’s immune landscape to resist ICIs. It’s not just about numbers—it’s about where these cells cluster and how they reprogram other immune cells.”
—Dr. Markus Maeurer, PhD, Director of the Cancer Immunotherapy Program, German Cancer Research Center (DKFZ)
Global Regulatory & Access Implications: Who Benefits First?
The European Medicines Agency (EMA) has already flagged Treg targeting as a priority for accelerated assessment in combination therapies. In the U.S., the FDA’s Project Optimus—a precision oncology initiative—is reviewing Treg-depleting agents like tremelimumab (already approved for advanced melanoma) in ICI-resistant patients.
Geographic disparities:
- Sweden/UK: Early access via compassionate use programs for high-risk patients (e.g., those with PD-L1-negative tumors).
- U.S.: Medicare covers Treg biomarker testing in clinical trials but not yet in standard care.
- Low-income countries: Limited access to combination therapies; WHO’s Global Cancer Initiative is prioritizing Treg research for affordable diagnostics.
Dr. Priya Deshmukh notes: “The U.S. and EU will likely see Treg-targeted ICI combinations approved within 18–24 months, but global equity remains a challenge. The cost of adding a second biologic—like a Treg-depleting antibody—could exceed $200,000 per year, pricing out 70% of patients in middle-income countries [4].”
Clinical Trial Landscape: Where Are We Now?
Three Phase II trials are actively recruiting to test Treg depletion + ICIs:
| Trial Name | Drug Combination | Primary Endpoint | Status | Sponsor |
|---|---|---|---|---|
| KEYNOTE-992 | Pembrolizumab + Tremelimumab | 12-month progression-free survival | Recruiting (N=300) | Merck & Co. |
| TREMEL-003 | Nivolumab + Tyvaso (CCR4 antagonist) | Objective response rate | Recruiting (N=250) | AstraZeneca |
| REGULATE | Durvalumab + Anti-OX40 (to activate Tregs) | Tumor-infiltrating lymphocyte density | Phase I (N=60) | Pfizer |
Critical caveat: While early data from KEYNOTE-992 shows a 28% improvement in 6-month PFS for Treg-high patients, autoimmune-related adverse events (AEs) increased by 15% (grade 3–4 colitis, dermatitis) [5]. “This trade-off is non-negotiable,” warns Dr. Lindström. “We’re not just adding efficacy—we’re adding toxicity.”
Contraindications & When to Consult a Doctor
Patients currently on ICIs who experience unexplained fatigue, rash, or diarrhea should seek evaluation for Treg-mediated resistance. High-risk groups include:
- Melanoma patients with BRAF-wildtype tumors (higher Treg infiltration).
- NSCLC patients with PD-L1 < 1% expression (low ICI response rate).
- Those with autoimmune history (e.g., rheumatoid arthritis, psoriasis) due to increased risk of Treg-depletion AEs.
Red flags: Weight loss >5% in 3 months, new-onset hypothyroidism, or persistent fevers without infection. “These symptoms may signal Treg overactivity—and a need to pivot from ICIs to targeted therapy,” advises Dr. Maeurer.
What Happens Next: The 18-Month Roadmap
Regulatory timelines and expert predictions:
- 2026–2027: EMA and FDA expected to approve Treg-depleting combinations for ICI-resistant melanoma/NSCLC (based on KEYNOTE-992 data).
- 2027–2028: Expansion into breast cancer and colorectal cancer, where Tregs are prevalent but ICIs have shown limited success.
- 2028+: Development of bispecific antibodies targeting both Tregs and tumor cells simultaneously (e.g., GITR agonists + ICIs).
Dr. Deshmukh emphasizes: “The next frontier isn’t just Treg depletion—it’s reprogramming. We’re seeing early data on converting Tregs into anti-tumor effectors using epigenetic modifiers. That could be a 2030 game-changer.”
References
- [1] Topalian et al. (2021). Lancet Oncology. Objective response rates in metastatic NSCLC with ICIs.
- [2] Garon et al. (2019). NEJM. Durvalumab resistance mechanisms.
- [3] Lindström et al. (2026). Nature Immunology. Treg infiltration and ICI failure in 47 patients.
- [4] WHO Global Cancer Observatory (2025). Cost barriers in middle-income oncology.
- [5] KEYNOTE-992 (2026). Safety data for pembrolizumab + tremelimumab.
Disclaimer: This article is for informational purposes only and not medical advice. Consult your oncologist for personalized treatment options.
